Clinical trial

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

NCT04067102

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2019-05-10

PhaseNA

Study timeline

Study start (actual)2019-05-10Date precision: day

Registry last updated2021-07-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancerunresolved

Interventions

Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamideDRUG

paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamideDRUG

Sponsors & collaborators

Hebei Medical University Fourth Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04067102 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.